Journal of Medicinal Chemistry · 2015 · 25 citations · 27 references
MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyNeuropharmacologyPharmacodynamicsDrug-receptor InteractionsLigand BindingLigand Binding KineticsPotency OptimizationReceptor PharmacologyReceptor-ligand InteractionsAffinity RetentionAgonist ActivityBinding Affinity EnhancementLigand Design For ReceptorsResidence TimeTarget-ligand Interactions
Analogues of the argininamide-type NPY Y1 receptor (Y1R) antagonist BIBP3226, bearing carbamoyl moieties at the guanidine group, revealed subnanomolar Ki values and caused depression of the maximal response to NPY (calcium assay) by up to 90% in a concentration- and time-dependent manner, suggesting insurmountable antagonism. To gain insight into the mechanism of binding of the synthesized compounds, a tritiated antagonist, (R)-N(α)-diphenylacetyl-N(ω)-[2-([2,3-(3)H]propionylamino)ethyl]aminocarbonyl-(4-hydroxybenzyl)arginin-amide ([(3)H]UR-MK299, [(3)H]38), was prepared. [(3)H]38 revealed a dissociation constant in the picomolar range (Kd 0.044 nM, SK-N-MC cells) and very high Y1R selectivity. Apart from superior affinity, a considerably lower target off-rate (t1/2 95 min) was characteristic of [(3)H]38 compared to that of the higher homologue containing a tetramethylene instead of an ethylene spacer (t1/2 3 min, Kd 2.0 nM). Y1R binding of [(3)H]38 was fully reversible and fully displaceable by nonpeptide antagonists and the agonist pNPY. Therefore, the insurmountable antagonism observed in the functional assay has to be attributed to the extended target-residence time, a phenomenon of relevance in drug research beyond the NPY receptor field.
27
Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets.
J.C. Reubi, Mathias Gugger, Beatrice Waser et al. · PubMed · 2001 · 190 citations
Medicine, Cancer Biology, Oncology +12